• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型二吡啶酸盐作为高浓度抗体溶液的粘度改性剂。

Novel salts of dipicolinic acid as viscosity modifiers for high concentration antibody solutions.

机构信息

Dosage Form Design & Development, MedImmune, Ltd., Aaron Klug Building, Granta Park, Cambridge CB21 6GH, UK.

Dosage Form Design & Development, MedImmune, Ltd., Aaron Klug Building, Granta Park, Cambridge CB21 6GH, UK; Department of Chemical Engineering and Biotechnology, University of Cambridge, Philippa Fawcett Drive, Cambridge CB3 0AS, UK.

出版信息

Int J Pharm. 2018 Sep 5;548(1):682-688. doi: 10.1016/j.ijpharm.2018.07.034. Epub 2018 Jul 20.

DOI:10.1016/j.ijpharm.2018.07.034
PMID:30009985
Abstract

Concentrated monoclonal antibody (mAb) solutions can lead to high viscosity as a result of protein-protein interactions and pose challenges for manufacture. Dipicolinic acid (DPA, pyridine-2,6-dicarboxylic acid) is a potential excipient for reduction of protein solution viscosity and here we describe new DPA salts with improved aqueous solubility. Crystallinity and solubility screens identified ethanolamine and diethanolamine as two promising counterions which generated crystalline, high melting point, anhydrous salt forms of DPA at 2:1 M stoichiometry. These salts significantly reduced the solution viscosity of five mAbs, equal to or better than that for the addition of arginine hydrochloride at equivalent osmolality. The presence of the DPA salts in solution did not significantly perturb the melting point of the mAbs, as determined by calorimetry, indicating an absence of any destabilization of protein conformation. Addition of the DPA salts to the mAb solutions stored at 5 °C over 6 months did not cause additional loss of the monomer fraction, though evidence of increased aggregation and fragmentation for three of the five mAbs was observed during 40 °C (accelerated and stressed) storage. Overall, this study demonstrates that ethanolamine-DPA and diethanolamine-DPA can serve as two novel excipients for viscosity reduction and could be considered by formulation scientists when developing highly concentrated mAb formulations.

摘要

浓缩的单克隆抗体(mAb)溶液会因蛋白-蛋白相互作用而导致高粘度,这给生产带来了挑战。二吡啶甲酸(DPA,吡啶-2,6-二羧酸)是一种有潜力的辅料,可以降低蛋白质溶液的粘度,在这里我们描述了具有改善的水溶性的新 DPA 盐。结晶性和溶解度筛选确定乙醇胺和二乙醇胺是两种有前途的抗衡离子,它们以 2:1 M 的化学计量生成结晶、高熔点、无水 DPA 盐形式。这些盐显著降低了五种 mAb 的溶液粘度,与等渗透压下添加盐酸精氨酸的效果相当或更好。差示扫描量热法(DSC)测定表明,DPA 盐的存在并没有显著改变 mAb 的熔点,表明这些盐没有使蛋白质构象不稳定。将 DPA 盐添加到 mAb 溶液中,在 5°C 下储存 6 个月,不会导致单体部分的额外损失,尽管在 40°C(加速和应激)储存期间观察到五种 mAb 中的三种的聚集和碎片化增加的证据。总的来说,这项研究表明,乙醇胺-DPA 和二乙醇胺-DPA 可以作为两种新型降低粘度的辅料,在开发高浓度 mAb 制剂时可以被制剂科学家考虑。

相似文献

1
Novel salts of dipicolinic acid as viscosity modifiers for high concentration antibody solutions.新型二吡啶酸盐作为高浓度抗体溶液的粘度改性剂。
Int J Pharm. 2018 Sep 5;548(1):682-688. doi: 10.1016/j.ijpharm.2018.07.034. Epub 2018 Jul 20.
2
Dipicolinic acid as a novel spore-inspired excipient for antibody formulation.二吡啶甲酸作为一种新型的受孢子启发用于抗体制剂的辅料。
Int J Pharm. 2017 Jun 30;526(1-2):332-338. doi: 10.1016/j.ijpharm.2017.05.012. Epub 2017 May 8.
3
Viscosity-Lowering Effect of Amino Acids and Salts on Highly Concentrated Solutions of Two IgG1 Monoclonal Antibodies.氨基酸和盐对两种IgG1单克隆抗体高浓度溶液的降粘效果
Mol Pharm. 2015 Dec 7;12(12):4478-87. doi: 10.1021/acs.molpharmaceut.5b00643. Epub 2015 Nov 12.
4
Studying Excipient Modulated Physical Stability and Viscosity of Monoclonal Antibody Formulations Using Small-Angle Scattering.利用小角散射研究赋形剂调节的单克隆抗体制剂的物理稳定性和黏度。
Mol Pharm. 2019 Oct 7;16(10):4319-4338. doi: 10.1021/acs.molpharmaceut.9b00687. Epub 2019 Sep 24.
5
Characterization of Excipient Effects on Reversible Self-Association, Backbone Flexibility, and Solution Properties of an IgG1 Monoclonal Antibody at High Concentrations: Part 1.在高浓度下对赋形剂对 IgG1 单克隆抗体的可逆自组装、主链柔韧性和溶液性质的影响进行表征:第 1 部分。
J Pharm Sci. 2020 Jan;109(1):340-352. doi: 10.1016/j.xphs.2019.06.005. Epub 2019 Jun 13.
6
Structure-activity relationship for hydrophobic salts as viscosity-lowering excipients for concentrated solutions of monoclonal antibodies.疏水盐作为降低单克隆抗体浓缩溶液黏度的辅料的构效关系。
Pharm Res. 2012 Nov;29(11):3102-9. doi: 10.1007/s11095-012-0802-9. Epub 2012 Jun 13.
7
A Formulation Development Approach to Identify and Select Stable Ultra-High-Concentration Monoclonal Antibody Formulations With Reduced Viscosities.一种制剂开发方法,用于识别和选择具有降低粘度的稳定超高浓度单克隆抗体制剂。
J Pharm Sci. 2017 Nov;106(11):3230-3241. doi: 10.1016/j.xphs.2017.06.017. Epub 2017 Jun 28.
8
Caffeine as a Viscosity Reducer for Highly Concentrated Monoclonal Antibody Solutions.咖啡因作为高浓度单克隆抗体溶液的粘度降低剂。
J Pharm Sci. 2021 Nov;110(11):3594-3604. doi: 10.1016/j.xphs.2021.06.030. Epub 2021 Jun 26.
9
The search for novel proline analogs for viscosity reduction and stabilization of highly concentrated monoclonal antibody solutions.寻找新型脯氨酸类似物以降低高浓度单克隆抗体溶液的黏度并稳定其溶液。
Int J Pharm. 2024 Apr 25;655:124055. doi: 10.1016/j.ijpharm.2024.124055. Epub 2024 Mar 28.
10
Characterizing monoclonal antibody formulations in arginine glutamate solutions using H NMR spectroscopy.使用核磁共振氢谱表征精氨酸谷氨酸溶液中的单克隆抗体制剂。
MAbs. 2016 Oct;8(7):1245-1258. doi: 10.1080/19420862.2016.1214786. Epub 2016 Aug 11.

引用本文的文献

1
Stability of Protein Pharmaceuticals: Recent Advances.蛋白质类药物的稳定性:最新进展
Pharm Res. 2024 Jul;41(7):1301-1367. doi: 10.1007/s11095-024-03726-x. Epub 2024 Jun 27.
2
Discovery of compounds with viscosity-reducing effects on biopharmaceutical formulations with monoclonal antibodies.发现对含单克隆抗体的生物制药制剂具有降低粘度作用的化合物。
Comput Struct Biotechnol J. 2022 Sep 26;20:5420-5429. doi: 10.1016/j.csbj.2022.09.035. eCollection 2022.
3
Utility of High Resolution 2D NMR Fingerprinting in Assessing Viscosity of Therapeutic Monoclonal Antibodies.
高分辨 2D NMR 指纹图谱在评估治疗性单克隆抗体黏度中的应用。
Pharm Res. 2022 Mar;39(3):529-539. doi: 10.1007/s11095-022-03200-6. Epub 2022 Feb 16.